Skip to main content
. 2016 Aug 22;7(41):67551–67573. doi: 10.18632/oncotarget.11509

Figure 2. Molecular targets and agents affecting specific targets in pediatric Hodgkin lymphoma.

Figure 2

Multiple pathways are implicated in Hodgkin lymphoma and thus present potential targets for therapy. The various targets and agents illustrate the need for future clinical trials to focus on synergistic action of inhibitors to kill tumor cells. The drugs are listed in blue boxes adjacent to the corresponding target. HDAC, histone deacetylase; MMAE, monomethyl auristatin E; PD1, programmed cell death protein 1; PD-L1, programmed death-ligand 1.